Overcoming Financial Toxicities of Cancer Care

Video

Barry Russo, CEO, The Center for Cancer and Blood Disorders, discusses ways to overcome financial toxicities associated with the cost of cancer care.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Exploring AFM13: Nieto on R/R Lymphoma Treatment Progress
Exploring AFM13: Nieto on R/R Lymphoma Treatment Progress
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
ADRIATIC Trial: Durvalumab Redefines Limited-Stage SCLC Treatment
ADRIATIC Trial: Durvalumab Redefines Limited-Stage SCLC Treatment
Discussing ASCO Strategies to Help Address the Workforce Shortage
Discussing ASCO Strategies to Help Address the Workforce Shortage
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
Management of ADC-Related AEs
Management of ADC-Related AEs
Pobel Translates PEACE-1 Trial Results Into Clinical Practice for mCSPC
Pobel Translates PEACE-1 Trial Results Into Clinical Practice for mCSPC
Seymour on the BCL-2 Pathway and Novel Therapeutic Strategies in CLL
Seymour on the BCL-2 Pathway and Novel Therapeutic Strategies in CLL
Related Content
Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

Targeted Oncology Staff
April 10th 2025
Article

During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.

Read More

BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Jordyn Sava
April 10th 2025
Article

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Read More

Exploring Innovations in Lymphoma Treatment With Russler-Germain

Exploring Innovations in Lymphoma Treatment With Russler-Germain

Jordyn Sava;David A. Russler-Germain, MD, PhD
February 27th 2025
Podcast

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Listen

FDA Awards Full Approval to Larotrectinib in NTRK+ Solid Tumors

FDA Awards Full Approval to Larotrectinib in NTRK+ Solid Tumors

Jordyn Sava
April 10th 2025
Article

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.

Read More

Model for MA Plan Reimbursement Needs Second Look

Model for MA Plan Reimbursement Needs Second Look

Leslie Busby, MD
April 10th 2025
Article

Addressing issues such as congestive heart failure is important to providing safe care to patients with cancer.

Read More